News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Orphan Australia Pty Ltd Receives Registration Approval for the New Dose Form DepoDur(R), Pacira Pharmaceuticals, Inc.'s Modified Release Injection of Morphine Sulfate


10/22/2007 10:20:57 AM

SAN DIEGO, Oct. 22 /PRNewswire/ -- Pacira Pharmaceuticals, Inc. today announced that Orphan Australia Pty Ltd, an Australian owned pharmaceutical company dedicated to providing novel, highly specialized pharmaceuticals, has been granted registration approval by the Therapeutic Goods Administration for DepoDur(R) in Australia. DepoDur, which was developed by and licensed from Pacira Pharmaceutical, Inc. and utilizes Pacira's DepoFoam(R) technology, is a novel, single dose modified-release formulation of morphine.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070618/PACIRALOGO)

The approved indication in Australia is "for the relief of post-operative pain, following major orthopedic, abdominal or pelvic surgery via the lumbar epidural route, at a maximum recommended dose of 10mg. Appropriate monitoring must be maintained for 48 hours."

A single injection of DepoDur into the lumbar epidural space may provide pain relief for up to 48 hours, following major orthopaedic, abdominal or pelvic surgery without the restrictions and potential complications associated with an indwelling epidural catheter.

"We are pleased to add an innovative product like DepoDur to our growing hospital product portfolio" said John Michailidis, the Chief Executive Officer of Orphan Australia. "It fits well with our philosophy of providing specialists with novel, highly specialized products which otherwise would not be available to the Australian market. We believe DepoDur will play an important role in managing post-operative pain in selected types of surgery".

DepoDur will be available in Australia from February 2008.

About Orphan Pharmaceuticals Pty Ltd.

Orphan Australia is a dynamic, rapidly growing, Australian owned company dedicated to providing novel, highly specialized products to treat serious or life-threatening conditions where treatment choice is limited or inadequate. DepoDur will be the first drug marketed by Orphan into the anaesthetic area, and adds to Orphan's strong presence in pain and palliative care, neurosurgery, gastroenterology, oncology, hematology, and nephrology. For additional information about Orphan Australia please visit the Company's website at http://www.orphan.com.au

About Pacira Pharmaceuticals Inc.

Pacira Pharmaceuticals Inc. is a wholly owned subsidy of Pacira Inc, a Delaware corporation, which is controlled and funded by a group of financial investors including Sanderling Ventures, HBM Bioventures (Cayman) LTD, OrbiMed Advisors, and MPM Capital. This business is based in San Diego, CA, and focuses on formulating, developing and manufacturing controlled-release injectable products based on two proprietary drug delivery platform: DepoFoam(R) and Biosphere(R). Revenues are generated from two marketed products: DepoCyt(R) for lymphomatous meningitis and DepoDur(R) for the treatment of post-surgical pain. For additional information about Pacira please visit the Company's website at http://www.pacira.com

john.michailidis@orphan.com.aumarkwalters@pacira.com



CONTACT: John Michailidis, Chief Executive Officer of Orphan Australia Pty
Ltd, +03 9769 5744, john.michailidis@orphan.com.au; or Mark Walters, V.P.,
Business and Commercial Development of Pacira Pharmaceuticals,
+1-858-625-2424, markwalters@pacira.com

Web site: http://www.pacira.com/
http://www.orphan.com.au/


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES